Intermediate Dose Melphalan for de novo Multiple Myeloma gives high complete response rate and durable long term survival

Reviewer: Julie Draznin Maltzman, MD
OncoLink
Ultima Vez Modificado: 7 de diciembre del 2002

Translation for this article does not exist